Astellas Signs License For Regeneron’s VelocImmune To Bolster Antibody Platform
Deal, valued at potentially $120 million, is Regeneron’s second for the human monoclonal antibody discovery technology.
Deal, valued at potentially $120 million, is Regeneron’s second for the human monoclonal antibody discovery technology.